Navigation Links
ESC reaffirms advice on cardiovascular risks associated with long-haul flights
Date:2/24/2009

Following a review by The Lancet of the medical issues associated with commercial air travel, the European Society of Cardiology has reaffirmed its advice about the risks of venous thromboembolism (VTE), whose risk, according to The Lancet, is increased "up to four-fold" by long-haul flight.

Dr Steen Kristensen, Vice-president of the ESC, says: "Long distance flying is associated with an increase in deep venous thrombosis, which in some cases may lead to clotting of the lungs. People who are immobile, pregnant, taking contraceptive pills or have had venous thrombosis in the past are particularly at risk. To minimise the risk it is important to drink plenty of non-alcoholic fluid and to walk (exercise) before and during the flight. The use of compression stockings is for some travelers an important way of preventing deep venous thrombosis."

Studies cited by The Lancet suggest that the risk of VTE increases when flight duration exceeds four hours. This raised risk is related to immobility, dehydration, and reduced oxygen in the cabin, as well as to individual risk factors such as obesity, recent surgery and predispositions to thrombosis (thrombophilias).

On the subject of risk Professor Kurt Huber, ESC spokesperson on Thrombosis, writes: "Prone to thromboembolic risk are those with a history of venous thrombosis or pulmonary embolism, but also those with a history of atherothrombotic diseases (for example, myocardial infarction or stroke) and those with heart failure, atrial fibrillation, and physical immobilisation." Professor Huber adds that even healthy people may develop thrombotic problems on a long-distance flight, notably pregnant women, women taking oral contraceptives (especially if they smoke) and the elderly. Those with concerns, he adds, should ask their doctor about their individual risk and the applicability of preventive measures, including medication.

With reference to the more serious cardiovascular complications of long-haul flight, Professor Panos E Vardas, president elect of the European Heart Rhythm Association (EHRA), commenting on behalf of the ESC, notes that loss of consciousness can occur during flight, for either benign or malignant reasons. The most common causes of benign episodes, explains Professor Vardas, include vasovagal syncope (fainting), whose most frequent cause is low blood pressure, especially in elderly patients who are taking certain medications.

Professor Vardas continues: "In the case of malignant arrhythmias, the loss of consciousness is most commonly attributed to ventricular tachycardia or ventricular fibrillation. Less dangerous cardiac arrhythmias which could also lead to loss of consciousness include paroxysmal atrial fibrillation, atrial flutter or paroxysmal atrial tachycardias.

The best course of action in the case of loss of consciousness is the currently recommended practice of ensuring that the patient remains in a lying down position, with the legs elevated. Simultaneously, if the syncopal episode lasts more than 30-40 seconds and if the automatic device advises defibrillation, the defibrillator should be activated.

Major European airlines already carry defibrillators and train their personnel to use them under the guidance of medical assistance on-ground. Hopefully, in the future,the use of automatic external defibrillators and the training of personnel will be extended to all commercial flights."

The European Society of Cardiology is currently preparing a policy statement on the safety of commercial air travel in cardiac patients.


'/>"/>

Contact: ESC Press Office
press@escardio.org
33-049-294-8627
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. China Sky One Medical, Inc. Reaffirms Guidance for 2008 Revenue and Net Income and Provides Business Update
2. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
3. HealthSouth Reaffirms Business Fundamentals and Full Year 2008 Guidance
4. AMDL Reaffirms 2008 Guidance and Provides Additional Information
5. Grocery Manufacturers Association: FDA Once Again Reaffirms Safety of Bisphenol A (BPA) for All Consumers
6. Lotus Pharmaceuticals, Inc. Reaffirms its Confidence in Meeting its Make Good Target for Fiscal Year 2008
7. Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
8. Gentiva(R) Health Services Announces First Quarter 2008 Results and Reaffirms Financial Outlook
9. Grocery Manufacturers Association: Canadian Risk Assessment Reaffirms Safety of Bisphenol A (BPA) for Adults and Children
10. Abbott Reports Double-Digit Sales and Earnings Growth in First Quarter and Reaffirms Full-Year Growth Outlook
11. Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... , ... April 26, 2017 , ... ... to improve the profitability of ready-to-drink, high-protein beverages by helping beverage manufacturers more ... to dairy proteins, providing direct cost savings as well as more stable pricing ...
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... ... The doctors at Wall Centre Dental are now expanding their practice by accepting ... receive dental care. The doctors offer three treatment options to put victims of ... at their dental office in Vancouver. Wall Centre Dental is currently welcoming even patients ...
(Date:4/25/2017)... GA (PRWEB) , ... April 25, 2017 , ... ... their neck and back pain with a reputable physician in their area, announces the ... CRM protects patient information for patients who are looking for reputable physicians to help ...
(Date:4/25/2017)... Fl (PRWEB) , ... April 25, 2017 , ... There ... Memorial Regional Hospital, according to a special report in the May issue of Consumer ... its highest quality ranking for results achieved during and after coronary bypass and ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Sorrento Therapeutics, Inc. ... clinical-stage biopharmaceutical company developing new treatments for cancer ... closing of its previously announced underwritten public offering ... a public offering price of $2.00 per share, ... offering expenses payable by Sorrento.  The net proceeds ...
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: